EurekaMag
+ Translate
+ Most Popular
The pigeon tick (Argas reflexus): its biology, ecology, and epidemiological aspects
Prevalence of hemoglobin abnormalities in Kebili (Tunisian South)
Lipogranuloma: a preventable complication of dacryocystorhinostomy
Value of basal plasma cortisol assays in the assessment of pituitary-adrenal insufficiency
Bees from the Belgian Congo. The acraensis group of Anthophora
Placing gingival retraction cord
Total serum IgE, allergy skin testing, and the radioallergosorbent test for the diagnosis of allergy in asthmatic children
Acariens plumicoles Analgesoidea parasites des oiseaux du Maroc
Injuries of terminal phalanges of the fingers in children
Biology of flowering and nectar production in pear (Pyrus communis)
Das Reliktvorkommen der Aspisviper (Vipera aspis L.) im Schwarzwald
Hydrological modelling of drained blanket peatland
Pathologic morphology and clinical significance of the anomalous origin of the left circumflex coronary artery from the right coronary artery. General review and autopsy analysis of 30 cases
Cyto genetic analyses of lymphocyte cultures after exposure to calcium cyclamate
Axelrodia riesei, a new characoid fish from Upper Rio Meta in Colombia With remarks concerning the genus Axelrodia and description of a similar, sympatric, Hyphessobrycon-species
Favorable evolution of a case of tuberculosis of pancreas under antibiotic action
RIFM fragrance ingredient safety assessment, Valencene, CAS Registry Number 4630-07-3
Parenteral microemulsions: an overview
Temperate pasture: management for grazing and conservation
Evaluation of a new coprocessed compound based on lactose and maize starch for tablet formulation
Thermal expansion and cracking of three confined water-saturated igneous rocks to 800C
Revision of the genera of the tribe Stigmoderini (Coleoptera: Buprestidae) a discussion of phylogenetic relationships
Anal tuberculosis. Report of a case
Gastric tuberculosis in the past and present
Adaptive responses of the cardiovascular system to prolonged spaceflight conditions: assessment with Holter monitoring

Isolation of therapeutic human monoclonal antibodies for varicella-zoster virus and the effect of light chains on the neutralizing activity


Isolation of therapeutic human monoclonal antibodies for varicella-zoster virus and the effect of light chains on the neutralizing activity



Journal of Medical Virology 79(6): 852-862



ISSN/ISBN: 0146-6615

PMID: 17457901

DOI: 10.1002/jmv.20838

Therapeutic antibodies against varicella-zoster virus (VZV) were isolated from a combinatorial library of human antibodies using a phage-display system. Purified gH:gL was used to screen the library, and approximately 300 clones were isolated. Eight kinds of Fab-cp3-fused molecules (clones 10, 24, 36, 60, 94, 120, 192, and 431) neutralized viral infectivity. After conversion of Fab-cp3 antibodies to the Fab-protein A form, the concentrations of antibodies showing 50% inhibition of plaque formation ranged from 0.12 to 400 nM. Clones 10, 24, 94, 120 and 431 neutralized wild strains without showing strain specificity and were further converted to human IgG(1). Two clones (24 and 94) were confirmed to react with gH:gL and VZV-infected cells. IgG of clone 94 prevented spreading of infected cells. Thus these antibodies exhibited the typical phenotype of anti-gH antibody. Next the contribution of light (L) chains to neutralizing activity was analyzed by comparing the effect of L chain of clones 10, 120, and 192 with the identical heavy chain on their neutralizing activity. The L chain in the Fab form of clone 94 was replaced by L chains of clones 10, 24, 36, and 60 and the neutralizing activity of these replaced antibodies was weaker than that of the prototype clone 94. When the kappa-L chain of clone 94 was replaced by the lambda-L chain of clone 24, this antibody possessed neutralizing activity despite the kappa-lambda class change. Thus, human antibody library against VZV-gH has been established and characterized the role of the L chain in VZV-neutralizing activity to engineering further an antibody with stronger neutralizing activity.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 013746165

Download citation: RISBibTeXText

Related references

Human monoclonal antibodies neutralizing varicella-zoster virus. Journal of Infectious Diseases 152(2): 280-285, 1985

Characterization of neutralizing domains on varicella-zoster virus glycoprotein E defined by monoclonal antibodies. Archives of Virology 142(2): 349-362, 1997

Expression of neutralizing recombinant human antibodies against Varicella Zoster virus for use as a potential prophylactic. Hybridoma 19(2): 143-149, 2000

Neutralizing human antibodies to varicella-zoster virus (VZV) derived from a VZV patient recombinant antibody library. Journal of General Virology 85(Pt 12): 3493-3500, 2004

Hybridomas producing human monoclonal antibodies against varicella-zoster virus. European Journal of Immunology 17(3): 359-364, 1987

IgG subclass distribution among antibodies to varicella-zoster virus in human varicella/zoster immunoglobulin preparations and the corresponding donor plasma. Journal of Biological Standardization 16(3): 157-164, 1988

Preparation of immune rabbit sera with neutralizing activity against human cytomegalovirus and varicella-zoster virus. Journal of General Virology 7(2): 169-171, 1970

Human leukocytes kill varicella-zoster virus-infected fibroblasts in the presence of murine monoclonal antibodies to virus-specific glycoproteins. Journal of Virology 54(1): 98-103, 1985

The fraction of varicella zoster virus-specific antibodies among all intrathecally-produced antibodies discriminates between patients with varicella zoster virus reactivation and multiple sclerosis. Fluids and Barriers of the Cns 11(1): 3, 2014

The age distribution of neutralizing antibodies against varicella-zoster virus in healthy individuals. Biken Journal 23(1): 9-14, 1980

Neutralizing antibodies induced by recombinant vaccinia virus expressing varicella-zoster virus gpIV. Journal of Virology 65(10): 5593-5596, 1991

Induction of neutralizing antibodies by varicella-zoster virus gpII glycoprotein expressed from recombinant vaccinia virus. Journal of General Virology 74: 491-494, 1993

Zoster encephalitis. Isolation of virus and measurement of varicella-zoster-specific antibodies in cerebrospinal fluid. American Journal of Medicine 73(5): 769-772, 1982

A single serum dilution method for the quantitation of neutralizing antibodies to varicella-zoster virus. Biken Journal 24(3): 109-118, 1981

Isolation and Characterization of Broad and Ultrapotent Human Monoclonal Antibodies with Therapeutic Activity against Chikungunya Virus. Cell Host and Microbe 18(1): 86-95, 2015